世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

創薬の人工知能(AI)市場:ソフトウェア・サービス毎、技術毎、用途毎、エンドユーザ毎、地域毎 - 2024年までの世界市場予測

Artificial Intelligence (AI) in Drug Discovery Market by Component (Software, Service), Technology (ML, DL), Application (Neurodegenerative Diseases, Immuno-Oncology, CVD), End User (Pharmaceutical & Biotechnology, CRO), Region - Global forecast to 2024

 

出版社 出版年月電子版価格 ページ数図表数
MarketsandMarkets
マーケッツアンドマーケッツ
2019年11月US$4,950
シングルユーザライセンス
156 176

サマリー

幅広い市場に関する調査レポートを出版しているマーケッツアンドマーケッツ(MarketsandMarkets)の創薬の人工知能(AI)市場に関する調査レポートです。

"“Growing number of cross-industry collaborations and partnerships and the need to control drug discovery & development costs and reduce the overall time taken in this process are the key factors driving the AI in the drug discovery market.”

The global AI in the drug discovery market is projected to reach USD 1,434 million by 2024 from USD 259 million in 2019, at a CAGR of 40.8% during the forecast period. Growth in this market is mainly driven by growing number of cross-industry collaborations and partnerships, the need to control drug discovery & development costs and reduce the overall time taken in this process, the rising adoption of cloud-based applications & services, and the impending patent expiry of blockbuster drugs. On the other hand, a lack of data sets in the field of drug discovery and the inadequate availability of skilled labor are some of the factors challenging the growth of the market.

“The immuno-oncology segment accounted for the largest share in 2019.”

Based on application, the artificial intelligence in the drug discovery market is segmented into neurodegenerative diseases, immuno-oncology, cardiovascular disease, metabolic diseases, and other applications. The immuno-oncology segment accounted for the largest share of 44.6% of the AI in the drug discovery market in 2018, owing to the increasing demand for effective cancer drugs. Neurodegenerative diseases form the fastest-growing application segment, with a CAGR of 42.9% during the forecast period. The ability of AI to discover drugs for complex diseases and the emphasis of market players on providing AI-based platforms for neurological diseases are responsible for the fast growth of this application segment.

“The Research centers and academic & government institutes segment to register the highest growth rate in the forecast period.”

Based on end-user, the AI in the drug discovery market is segmented into pharmaceutical & biotechnology companies, contract research organizations, and research centers and academic, & government institutes. In 2018, the pharmaceutical & biotechnology companies segment accounted for the largest share in the AI in the drug discovery market. AI and machine learning to allow pharmaceutical companies to operate more efficiently and substantially improve success rates at the early stages of drug development. This is one of the major factors driving the growth of this market.

Research centers and academic & government institutes are expected to show the highest growth of 43.6%.during the forecast period. The growth of the CROs segment is tied to that of pharmaceutical & biotechnology companies, as the rise in research and production activity will ensure sustained demand for contract services.

“North America to be the largest and the fastest-growing regional market.”

North America, which comprises the US, Canada, and Mexico, forms the largest market for AI in drug discovery. These countries have been early adopters of AI technology in drug discovery and development. In the North American market, the US is a significant contributor. Also, prominent AI technology providers, such as IBM, Google, Microsoft, NVIDIA, and Intel, are headquartered in the US; their strong presence is a key contributor to market growth. Other drivers include the well-established pharmaceutical industry, high focus on R&D & substantial investment, and the presence of globally leading pharmaceutical companies. These are some of the major factors responsible for the large share and high growth rate of this market.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 (28%), Tier 2 (42%), and Tier 3 (30%)
• By Designation: C-level (30%), D-level (34%), and Others (36%)
• By Region: North America (46%), Europe (25%), Asia (18%), and the RoW (11%)

List of Companies Profiled in the Report

• IBM Corporation (US)
• Microsoft (US), Google (US)
• NVIDIA Corporation (US)
• Atomwise, Inc. (US)
• Deep Genomics (Canada)
• Cloud Pharmaceuticals (US)
• Insilico Medicine (US)
• Benevolent AI (UK)
• Exscientia (UK)
• Cyclica (Canada)
• BIOAGE (US)
• Numerate (US)
• Numedii (US)
• Envisagenics (US)
• twoXAR (US)
• OWKIN, Inc. (US)
• XtalPi (US)
• Verge Genomics (US)
• Berg LLC (US)

Research Coverage:

This report provides a study of the AI in the drug discovery market. It aims at estimating the size and future growth potential of the market across different segments, such as offering, technology, application, end-user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of revenue numbers for the overall AI in drug discovery market and its subsegments. This report will also help stakeholders understand the competitive landscape, and gain insights to better position their business and make suitable go-to-market strategies. It will also enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, challenges, and opportunities.
 



目次

1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 MARKET SCOPE 18
1.3.1 MARKETS COVERED 18
1.3.2 YEARS CONSIDERED FOR THE STUDY 19
1.4 CURRENCY 19
1.5 LIMITATIONS 19
1.6 STAKEHOLDERS 20
2 RESEARCH METHODOLOGY 21
2.1 RESEARCH DATA 21
2.1.1 SECONDARY SOURCES 22
2.1.1.1 Key data from secondary sources 23
2.1.2 PRIMARY SOURCES 23
2.1.2.1 Key data from primary sources 24
2.1.2.2 Key industry insights 25
2.2 MARKET SIZE ESTIMATION 26
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 28
2.4 ASSUMPTIONS FOR THE STUDY 29
3 EXECUTIVE SUMMARY 30
4 PREMIUM INSIGHTS 35
4.1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET OVERVIEW 35
4.2 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING (2019–2024) 36
4.3 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE & REGION (2018) 37
4.4 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 38
5 MARKET OVERVIEW 39
5.1 INTRODUCTION 39
5.2 MARKET DYNAMICS 39
5.2.1 MARKET DRIVERS 40
5.2.1.1 Growing number of cross-industry collaborations and partnerships 40
5.2.1.2 Need to control drug discovery & development costs and reduce time 41
5.2.1.3 Patent expiry 41

5.2.2 MARKET OPPORTUNITIES 42
5.2.2.1 Growing biotechnology industry 42
5.2.2.2 Emerging markets 42
5.2.3 MARKET CHALLENGES 42
5.2.3.1 Limited availability of data sets 42
6 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING 43
6.1 INTRODUCTION 44
6.2 SOFTWARE 44
6.2.1 BENEFITS OFFERED BY SOFTWARE IN DRUG DISCOVERY & STRONG DEMAND AMONG END USERS ARE DRIVING MARKET GROWTH 44
6.3 SERVICES 46
6.3.1 SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 46
7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY 48
7.1 INTRODUCTION 49
7.2 MACHINE LEARNING 49
7.2.1 INCREASING ADOPTION OF ML BY RESEARCH CENTERS & PHARMACEUTICAL COMPANIES TO SUPPORT THE GROWTH OF THIS SEGMENT 49
7.2.2 DEEP LEARNING 51
7.2.3 SUPERVISED LEARNING 54
7.2.4 REINFORCEMENT LEARNING 56
7.2.5 UNSUPERVISED LEARNING 57
7.2.6 OTHER MACHINE LEARNING TECHNOLOGIES 59
7.3 OTHER TECHNOLOGIES 61
8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION 63
8.1 INTRODUCTION 64
8.2 IMMUNO-ONCOLOGY 64
8.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE IN THE SUPPLY OF CANCER DRUGS ARE THE KEY FACTORS DRIVING MARKET GROWTH 64
8.3 NEURODEGENERATIVE DISEASES 66
8.3.1 AI IS BEING USED TO RESOLVE EXISTING CHALLENGES IN NEUROLOGICAL DISEASE DRUG DEVELOPMENT 66
8.4 CARDIOVASCULAR DISEASES 68
8.4.1 RISING DEMAND FOR CVD DRUGS IS DRIVING MARKET GROWTH 68
8.5 METABOLIC DISEASES 70
8.5.1 ROLE OF AI IN UNCOVERING SMALL-MOLECULE THERAPIES IS DRIVING ITS ADOPTION IN THIS SEGMENT 70
8.6 OTHER APPLICATIONS 72

9 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER 74
9.1 INTRODUCTION 75
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 75
9.2.1 RISING DEMAND FOR SOLUTIONS TO CUT TIME AND COSTS OF DRUG DEVELOPMENT HAVE DRAWN END-USER ATTENTION TO AI 75
9.3 CONTRACT RESEARCH ORGANIZATIONS 78
9.3.1 GROWING TREND OF OUTSOURCING PROVIDES SIGNIFICANT OPPORTUNITIES FOR CROS 78
9.4 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES 80
9.4.1 THIS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 80
10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION 82
10.1 INTRODUCTION 83
10.2 NORTH AMERICA 83
10.2.1 US 86
10.2.1.1 Strong economy and trend of early adoption of technologies are driving market growth in the US 86
10.2.2 CANADA 89
10.2.2.1 Growing research on AI technologies and emergence of new AI-based start-ups will support the market in Canada 89
10.2.3 MEXICO 91
10.2.3.1 Government initiatives will support market growth in Mexico 91
10.3 EUROPE 92
10.3.1 UK 95
10.3.1.1 The UK holds the largest share of the European market 95
10.3.2 GERMANY 98
10.3.2.1 Government support and favorable training programs are major market drivers in Germany 98
10.3.3 FRANCE 99
10.3.3.1 Strong government support and favorable strategies & initiatives form key drivers of the market in France 99
10.3.4 REST OF EUROPE 101
10.4 ASIA PACIFIC 103
10.4.1 JAPAN 105
10.4.1.1 Japan dominates the APAC market for AI in drug discovery 105
10.4.2 CHINA 106
10.4.2.1 Growing CMOs market and cross-industry collaborations are factors responsible for the growth of the market in China 106
10.4.3 INDIA 108
10.4.3.1 Steady adoption of AI technologies will drive market growth in India 108
10.4.4 REST OF ASIA PACIFIC 110
10.5 REST OF THE WORLD 112
11 COMPETITIVE LANDSCAPE 114
11.1 OVERVIEW 114
11.2 MARKET SHARE ANALYSIS 116
11.3 COMPETITIVE LEADERSHIP MAPPING 117
11.3.1 VISIONARY LEADERS 117
11.3.2 DYNAMIC DIFFERENTIATORS 117
11.3.3 INNOVATORS 117
11.3.4 EMERGING COMPANIES 117
11.4 COMPETITIVE SITUATION AND TRENDS 119
11.4.1 PRODUCT LAUNCHES AND ENHANCEMENTS 119
11.4.2 EXPANSIONS 119
11.4.3 ACQUISITIONS 120
11.4.4 OTHER STRATEGIES 120
12 COMPANY PROFILES 121
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 MICROSOFT CORPORATION 121
12.2 NVIDIA CORPORATION 123
12.3 IBM CORPORATION 125
12.4 GOOGLE (A SUBSIDIARY OF ALPHABET INC.) 127
12.5 ATOMWISE, INC. 130
12.6 DEEP GENOMICS 132
12.7 CLOUD PHARMACEUTICALS, INC. 133
12.8 INSILICO MEDICINE 134
12.9 BENEVOLENTAI 135
12.10 EXSCIENTIA 136
12.11 CYCLICA 138
12.12 BIOAGE 140
12.13 NUMERATE 141
12.14 NUMEDII, INC. 142
12.15 ENVISAGENICS 143
12.16 TWOXAR, INCORPORATED 144
12.17 OWKIN, INC. 145
12.18 XTALPI, INC. 146
12.19 VERGE GENOMICS 147
12.20 BERG LLC 148
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

13 APPENDIX 149
13.1 DISCUSSION GUIDE 149
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 152
13.3 AVAILABLE CUSTOMIZATIONS 154
13.4 RELATED REPORTS 154
13.5 AUTHOR DETAILS 155

 

LIST OF TABLES

TABLE 1 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS (2017–2019) 40
TABLE 2 INDICATIVE LIST OF DRUGS LOSING PATENT IN 2019 41
TABLE 3 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING,
2017–2024 (USD MILLION) 44
TABLE 4 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE,
BY REGION, 2017–2024 (USD MILLION) 45
TABLE 5 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2017–2024 (USD MILLION) 45
TABLE 6 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2017–2024 (USD MILLION) 45
TABLE 7 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2017–2024 (USD MILLION) 46
TABLE 8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES,
BY REGION, 2017–2024 (USD MILLION) 46
TABLE 9 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2017–2024 (USD MILLION) 47
TABLE 10 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2017–2024 (USD MILLION) 47
TABLE 11 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES,
BY COUNTRY, 2017–2024 (USD MILLION) 47
TABLE 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 49
TABLE 13 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2017–2024 (USD MILLION) 50
TABLE 14 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY REGION, 2017–2024 (USD MILLION) 50
TABLE 15 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 50
TABLE 16 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 51
TABLE 17 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 51
TABLE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING,
BY REGION, 2017–2024 (USD MILLION) 52
TABLE 19 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 52
TABLE 20 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 53
TABLE 21 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 53
TABLE 22 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY REGION, 2017–2024 (USD MILLION) 54
TABLE 23 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 54
TABLE 24 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 55
TABLE 25 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 55
TABLE 26 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY REGION, 2017–2024 (USD MILLION) 56
TABLE 27 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 56
TABLE 28 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 57
TABLE 29 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 57
TABLE 30 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY REGION, 2017–2024 (USD MILLION) 58
TABLE 31 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 58
TABLE 32 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 58
TABLE 33 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 59
TABLE 34 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY REGION, 2017–2024 (USD MILLION) 59
TABLE 35 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY,
2017–2024 (USD MILLION) 60
TABLE 36 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2017–2024 (USD MILLION) 60
TABLE 37 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2017–2024 (USD MILLION) 60
TABLE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2017–2024 (USD MILLION) 61
TABLE 39 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017–2024 (USD MILLION) 61
TABLE 40 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017–2024 (USD MILLION) 62
TABLE 41 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017–2024 (USD MILLION) 62
TABLE 42 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 64
TABLE 43 INDICATIVE LIST OF INITIATIVES IN IMMUNO-ONCOLOGY DRUG DEVELOPMENT 65
TABLE 44 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY REGION, 2017–2024 (USD MILLION) 65
TABLE 45 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2017–2024 (USD MILLION) 65
TABLE 46 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2017–2024 (USD MILLION) 66
TABLE 47 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2017–2024 (USD MILLION) 66
TABLE 48 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2017–2024 (USD MILLION) 67
TABLE 49 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2017–2024 (USD MILLION) 67
TABLE 50 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2017–2024 (USD MILLION) 68
TABLE 51 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2017–2024 (USD MILLION) 68
TABLE 52 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT 69
TABLE 53 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2017–2024 (USD MILLION) 69
TABLE 54 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2017–2024 (USD MILLION) 69
TABLE 55 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2017–2024 (USD MILLION) 70
TABLE 56 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2017–2024 (USD MILLION) 70
TABLE 57 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY REGION, 2017–2024 (USD MILLION) 71
TABLE 58 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2017–2024 (USD MILLION) 71
TABLE 59 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2017–2024 (USD MILLION) 71
TABLE 60 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2017–2024 (USD MILLION) 72
TABLE 61 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY REGION, 2017–2024 (USD MILLION) 72
TABLE 62 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017–2024 (USD MILLION) 73
TABLE 63 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017–2024 (USD MILLION) 73
TABLE 64 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017–2024 (USD MILLION) 73
TABLE 65 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 75
TABLE 66 INDICATIVE LIST OF DEVELOPMENTS 76
TABLE 67 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2017–2024 (USD MILLION) 76
TABLE 68 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2017–2024 (USD MILLION) 77
TABLE 69 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2017–2024 (USD MILLION) 77
TABLE 70 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2017–2024 (USD MILLION) 77
TABLE 71 INDICATIVE LIST OF COLLABORATIONS WITH CROS 78
TABLE 72 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2017–2024 (USD MILLION) 78
TABLE 73 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2017–2024 (USD MILLION) 79
TABLE 74 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2017–2024 (USD MILLION) 79
TABLE 75 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2017–2024 (USD MILLION) 79
TABLE 76 INDICATIVE LIST OF RESEARCH COLLABORATIONS 80
TABLE 77 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY REGION,
2017–2024 (USD MILLION) 80
TABLE 78 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET
FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES,
2017–2024 (USD MILLION) 81
TABLE 79 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR
RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES,
2017–2024 (USD MILLION) 81
TABLE 80 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR
RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES,
2017–2024 (USD MILLION) 81
TABLE 81 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION,
2017–2024 (USD MILLION) 83
TABLE 82 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY COUNTRY, 2017–2024 (USD MILLION) 85
TABLE 83 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY OFFERING, 2017–2024 (USD MILLION) 85
TABLE 84 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY TECHNOLOGY, 2017–2024 (USD MILLION) 85
TABLE 85 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY APPLICATION, 2017–2024 (USD MILLION) 86
TABLE 86 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY END USER, 2017–2024 (USD MILLION) 86
TABLE 87 US: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS 87
TABLE 88 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 87
TABLE 89 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 88
TABLE 90 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 88
TABLE 91 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 88
TABLE 92 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 89
TABLE 93 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY TECHNOLOGY, 2017–2024 (USD MILLION) 90
TABLE 94 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY APPLICATION, 2017–2024 (USD MILLION) 90
TABLE 95 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 90
TABLE 96 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 91
TABLE 97 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY TECHNOLOGY, 2017–2024 (USD MILLION) 91
TABLE 98 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY APPLICATION, 2017–2024 (USD MILLION) 92
TABLE 99 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 92
TABLE 100 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 94
TABLE 101 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 94
TABLE 102 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY TECHNOLOGY, 2017–2024 (USD MILLION) 94
TABLE 103 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY APPLICATION, 2017–2024 (USD MILLION) 95
TABLE 104 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 95
TABLE 105 UK: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS 96
TABLE 106 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 96
TABLE 107 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 97
TABLE 108 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 97
TABLE 109 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 97
TABLE 110 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY OFFERING, 2017–2024 (USD MILLION) 98
TABLE 111 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY TECHNOLOGY, 2017–2024 (USD MILLION) 98
TABLE 112 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY APPLICATION, 2017–2024 (USD MILLION) 99
TABLE 113 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY END USER, 2017–2024 (USD MILLION) 99
TABLE 114 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 100
TABLE 115 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY TECHNOLOGY, 2017–2024 (USD MILLION) 100
TABLE 116 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY APPLICATION, 2017–2024 (USD MILLION) 100
TABLE 117 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 101
TABLE 118 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 101
TABLE 119 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 102
TABLE 120 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 102
TABLE 121 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 102
TABLE 122 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 103
TABLE 123 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 103
TABLE 124 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 104
TABLE 125 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 104
TABLE 126 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 104
TABLE 127 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 105
TABLE 128 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 105
TABLE 129 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 106
TABLE 130 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 106
TABLE 131 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 107
TABLE 132 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 107
TABLE 133 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 108
TABLE 134 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 108
TABLE 135 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 109
TABLE 136 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 109
TABLE 137 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 109
TABLE 138 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 110
TABLE 139 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 110
TABLE 140 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY TECHNOLOGY, 2017–2024 (USD MILLION) 111
TABLE 141 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY APPLICATION, 2017–2024 (USD MILLION) 111
TABLE 142 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 111
TABLE 143 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 112
TABLE 144 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 112
TABLE 145 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 113
TABLE 146 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 113
TABLE 147 PRODUCT LAUNCHES AND ENHANCEMENTS, 2016–2019 119
TABLE 148 EXPANSIONS, 2016–2019 119
TABLE 149 ACQUISITIONS, 2016–2019 120
TABLE 150 OTHER STRATEGIES, 2016–2019 120

 

LIST OF FIGURES

FIGURE 1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY: MARKET SEGMENTATION 18
FIGURE 2 RESEARCH DESIGN 21
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS 25
FIGURE 4 BOTTOM-UP APPROACH 27
FIGURE 5 TOP-DOWN APPROACH 27
FIGURE 6 DATA TRIANGULATION METHODOLOGY 28
FIGURE 7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING,
2019 VS. 2024 (USD MILLION) 30
FIGURE 8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2019–2024 31
FIGURE 9 ARTIFICIAL LEARNING IN DRUG DISCOVERY MARKET, BY APPLICATION,
2019 VS. 2024 (USD MILLION) 32
FIGURE 10 ARTIFICIAL LEARNING IN DRUG DISCOVERY MARKET, BY END USER,
2019 VS. 2024 (USD MILLION) 33
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET 34
FIGURE 12 NEED TO CONTROL DRUG DISCOVERY & DEVELOPMENT COSTS IS A MAJOR FACTOR DRIVING THE ADOPTION OF AI IN DRUG DISCOVERY SOLUTIONS 35
FIGURE 13 SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING
THE FORECAST PERIOD 36
FIGURE 14 DEEP LEARNING SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE
IN 2018 37
FIGURE 15 NORTH AMERICA IS THE FASTEST-GROWING REGIONAL MARKET FOR AI IN DRUG DISCOVERY 38
FIGURE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 39
FIGURE 17 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG
DISCOVERY MARKET SNAPSHOT 84
FIGURE 18 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT 93
FIGURE 19 KEY PLAYERS ADOPTED ORGANIC AS WELL AS INORGANIC GROWTH STRATEGIES 114
FIGURE 20 MARKET EVOLUTION FRAMEWORK 115
FIGURE 21 AI IN DRUG DISCOVERY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018 116
FIGURE 22 COMPETITIVE LEADERSHIP MAPPING OF THE AI IN DRUG DISCOVERY MARKET 118
FIGURE 23 MICROSOFT CORPORATION: COMPANY SNAPSHOT 121
FIGURE 24 NVIDIA CORPORATION: COMPANY SNAPSHOT 123
FIGURE 25 IBM CORPORATION: COMPANY SNAPSHOT 125
FIGURE 26 ALPHABET: COMPANY SNAPSHOT 127
 

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る